On Dec 8, 2025, the US Food and Drug Administration (FDA) approved the Flow Neuroscience transcranial Direct Current Stimulation (tDCS) device for the treatment of “moderate to severe major depressive disorder (MDD). What the the implications?
Changes in Oxygen Metabolism Biomarkers of Ischemic Tissue Treated With Electrical Stimulation
High-Definition Transcranial Electrical Stimulation (HD-tES): Prospects in Psychiatric and Neurological Disorders)
The Neural Engineering Group at The City College of New York analyzes nervous system function at multiple scales spanning sub-cellular, single cell, tissue, animal, to human cognitive levels. Similarly, our translational research and development program integrates experimental testing, medical device development, and clinical trials – with the over-arching goal of improving human health through engineering innovation.